Drug discovery

In drug discovery, chemical biology, and organic optoelectronic materials development, rework is often not caused by the “core function” failing. More commonly, it stems from insufficient stability and controllability of the results: along the same route and within the same structural ...

In drug discovery, agrochemical development, and industrial formulations, one of the most frequent reasons for rework is: the activity is there, but the compound is not sufficiently “usable.”

In drug discovery, catalysis, and materials chemistry, quinoline and isoquinoline are often treated as “pretty similar N-heteroaromatics.” But in real experiments, the differences most likely to trigger rework often come from one key factor: the position of the ring nitrogen.

7-membered N-heterocycles—as a structural module—are often used because.

In drug discovery, many molecules end up stuck in the same awkward spot: potency is good, but exposure is insufficient; selectivity looks fine, but metabolism is too fast; in vitro is beautiful, yet in vivo distribution is disappointing. In those moments, you usually don’t want to rebuild the ...

Although target-based drug discovery is currently the dominant approach to drug discovery and development, the latest comprehensive assessment shows that its results are not as good as they could be. The number of drugs discovered by this approach is relatively small, and their therapeutic ...